The Clinical Relevance of the Clopidogrel–Proton Pump Inhibitor Interaction

go back to reference Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., & Casey, D. E., Jr. (2007). ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Journal of the American College of Cardiology, 50(7), e1–e157. Epub 2007/08/19.PubMedCrossRef Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., & Casey, D. E., Jr. (2007). ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Journal of the American College of Cardiology, 50(7), e1–e157. Epub 2007/08/19.PubMedCrossRef

go back to reference Bhatt, D. L., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F. K., & Furberg, C. D. (2008). ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation, 118(18), 1894–1909. Epub 2008/10/07.PubMedCrossRef Bhatt, D. L., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F. K., & Furberg, C. D. (2008). ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation, 118(18), 1894–1909. Epub 2008/10/07.PubMedCrossRef

go back to reference Shuldiner, A. R., O'Connell, J. R., Bliden, K. P., Gandhi, A., Ryan, K., & Horenstein, R. B. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA:The Journal of the American Medical Association, 302(8), 849–857. Epub 2009/08/27.PubMedCrossRef Shuldiner, A. R., O'Connell, J. R., Bliden, K. P., Gandhi, A., Ryan, K., & Horenstein, R. B. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA:The Journal of the American Medical Association, 302(8), 849–857. Epub 2009/08/27.PubMedCrossRef

go back to reference Hulot, J. S., Bura, A., Villard, E., Azizi, M., Remones, V., & Goyenvalle, C. (2006). Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood, 108(7), 2244–2247. Epub 2006/06/15.PubMedCrossRef Hulot, J. S., Bura, A., Villard, E., Azizi, M., Remones, V., & Goyenvalle, C. (2006). Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood, 108(7), 2244–2247. Epub 2006/06/15.PubMedCrossRef

go back to reference Angiolillo, D. J., Gibson, C. M., Cheng, S., Ollier, C., Nicolas, O., & Bergougnan, L. (2011). Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clinical Pharmacology and Therapeutics, 89(1), 65–74. Epub 2010/09/17.PubMedCrossRef Angiolillo, D. J., Gibson, C. M., Cheng, S., Ollier, C., Nicolas, O., & Bergougnan, L. (2011). Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clinical Pharmacology and Therapeutics, 89(1), 65–74. Epub 2010/09/17.PubMedCrossRef

go back to reference O'Donoghue, M. L., Braunwald, E., Antman, E. M., Murphy, S. A., Bates, E. R., & Rozenman, Y. (2009). Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet, 374(9694), 989–997. Epub 2009/09/04.PubMedCrossRef O'Donoghue, M. L., Braunwald, E., Antman, E. M., Murphy, S. A., Bates, E. R., & Rozenman, Y. (2009). Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet, 374(9694), 989–997. Epub 2009/09/04.PubMedCrossRef

go back to reference Bates, E. R., Lau, W. C., & Angiolillo, D. J. (2011). Clopidogrel–drug interactions. Journal of the American College of Cardiology, 57(11), 1251–1263. Epub 2011/03/12.PubMedCrossRef Bates, E. R., Lau, W. C., & Angiolillo, D. J. (2011). Clopidogrel–drug interactions. Journal of the American College of Cardiology, 57(11), 1251–1263. Epub 2011/03/12.PubMedCrossRef

go back to reference Mega, J. L., Simon, T., Collet, J. P., Anderson, J. L., Antman, E. M., & Bliden, K. (2010). Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA: The Journal of the American Medical Association, 304(16), 1821–1830. doi:16. Epub 2010/10/28.CrossRef Mega, J. L., Simon, T., Collet, J. P., Anderson, J. L., Antman, E. M., & Bliden, K. (2010). Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA: The Journal of the American Medical Association, 304(16), 1821–1830. doi:16. Epub 2010/10/28.CrossRef

go back to reference Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., & Brandt, J. T. (2009). Cytochrome p-450 polymorphisms and response to clopidogrel. The New England Journal of Medicine, 360(4), 354–362. Epub 2008/12/25.PubMedCrossRef Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., & Brandt, J. T. (2009). Cytochrome p-450 polymorphisms and response to clopidogrel. The New England Journal of Medicine, 360(4), 354–362. Epub 2008/12/25.PubMedCrossRef

go back to reference Zhang, H., Ragueneau-Majlessi, I., & Levy, R. H. (2009). Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition. Drug Metabolism Letters, 3(4), 287–289. Epub 2009/12/10.PubMedCrossRef Zhang, H., Ragueneau-Majlessi, I., & Levy, R. H. (2009). Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition. Drug Metabolism Letters, 3(4), 287–289. Epub 2009/12/10.PubMedCrossRef

go back to reference Sibbing, D., Morath, T., Stegherr, J., Braun, S., Vogt, W., & Hadamitzky, M. (2009). Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thrombosis and Haemostasis, 101(4), 714–719. Epub 2009/04/08.PubMed Sibbing, D., Morath, T., Stegherr, J., Braun, S., Vogt, W., & Hadamitzky, M. (2009). Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thrombosis and Haemostasis, 101(4), 714–719. Epub 2009/04/08.PubMed

go back to reference Neubauer, H., Engelhardt, A., Krueger, J. C., Lask, S., Boergel, J., Muegge, A., et al. (2010). Pantoprazole does not influence the antiplatelet effect of clopidogrel—A whole blood aggregometry study after coronary stenting. Journal of Cardiovascular Pharmacology, 56, 91–97.PubMedCrossRef Neubauer, H., Engelhardt, A., Krueger, J. C., Lask, S., Boergel, J., Muegge, A., et al. (2010). Pantoprazole does not influence the antiplatelet effect of clopidogrel—A whole blood aggregometry study after coronary stenting. Journal of Cardiovascular Pharmacology, 56, 91–97.PubMedCrossRef

go back to reference Small, D. S., Farid, N. A., Payne, C. D., Weerakkody, G. J., Li, Y. G., & Brandt, J. T. (2008). Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Journal of Clinical Pharmacology, 48(4), 475–484. Epub 2008/02/28.PubMedCrossRef Small, D. S., Farid, N. A., Payne, C. D., Weerakkody, G. J., Li, Y. G., & Brandt, J. T. (2008). Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Journal of Clinical Pharmacology, 48(4), 475–484. Epub 2008/02/28.PubMedCrossRef

go back to reference Gurbel, P. A., Tantry, U. S., & Shuldiner, A. R. (2010). Letter by Gurbel et al. regarding article, “Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement”. Circulation, 122(14), e478. author reply e9. Epub 2010/10/06.PubMedCrossRef Gurbel, P. A., Tantry, U. S., & Shuldiner, A. R. (2010). Letter by Gurbel et al. regarding article, “Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement”. Circulation, 122(14), e478. author reply e9. Epub 2010/10/06.PubMedCrossRef

go back to reference Price, M. J., Tantry, U. S., & Gurbel, P. A. (2011). The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. Reviews in Cardiovascular Medicine, 12(1), 1–12. Epub 2011/05/07.PubMed Price, M. J., Tantry, U. S., & Gurbel, P. A. (2011). The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. Reviews in Cardiovascular Medicine, 12(1), 1–12. Epub 2011/05/07.PubMed

go back to reference Munoz-Torrero, J. F., Escudero, D., Suarez, C., Sanclemente, C., Pascual, M. T., & Zamorano, J. (2011). Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry. Journal of Cardiovascular Pharmacology, 57(1), 13–19.PubMedCrossRef Munoz-Torrero, J. F., Escudero, D., Suarez, C., Sanclemente, C., Pascual, M. T., & Zamorano, J. (2011). Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry. Journal of Cardiovascular Pharmacology, 57(1), 13–19.PubMedCrossRef

go back to reference Charlot, M., Grove, E. L., Hansen, P. R., Olesen, J. B., Ahlehoff, O., Selmer, C., et al. (2011). Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ, 342, d2690.PubMedCrossRef Charlot, M., Grove, E. L., Hansen, P. R., Olesen, J. B., Ahlehoff, O., Selmer, C., et al. (2011). Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ, 342, d2690.PubMedCrossRef

go back to reference Laine, L., & Hennekens, C. (2010). Proton pump inhibitor and clopidogrel interaction: fact or fiction? American Journal of Gastroenterology, 105(1), 34–41.PubMedCrossRef Laine, L., & Hennekens, C. (2010). Proton pump inhibitor and clopidogrel interaction: fact or fiction? American Journal of Gastroenterology, 105(1), 34–41.PubMedCrossRef

go back to reference Simon, T., Steg, P. G., Gilard, M., Blanchard, D., Bonello, L., Hanssen, M., et al. (2011). Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation, 123(5), 474–482.PubMedCrossRef Simon, T., Steg, P. G., Gilard, M., Blanchard, D., Bonello, L., Hanssen, M., et al. (2011). Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation, 123(5), 474–482.PubMedCrossRef

go back to reference Juurlink, D. N., Gomes, T., Ko, D. T., Szmitko, P. E., Austin, P. C., & Tu, J. V. (2009). A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ: Canadian Medical Association Journal, 180(7), 713–718.PubMedCrossRef Juurlink, D. N., Gomes, T., Ko, D. T., Szmitko, P. E., Austin, P. C., & Tu, J. V. (2009). A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ: Canadian Medical Association Journal, 180(7), 713–718.PubMedCrossRef

go back to reference Ho, P. M., Maddox, T. M., Wang, L., Fihn, S. D., Jesse, R. L., Peterson, E. D., et al. (2009). Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA: The Journal of the American Medical Association, 301(9), 937–944.CrossRef Ho, P. M., Maddox, T. M., Wang, L., Fihn, S. D., Jesse, R. L., Peterson, E. D., et al. (2009). Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA: The Journal of the American Medical Association, 301(9), 937–944.CrossRef

go back to reference Li, X. Q., Andersson, T. B., Ahlstrom, M., & Weidolf, L. (2004). Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metabolism and Disposition, 32(8), 821–827.PubMedCrossRef Li, X. Q., Andersson, T. B., Ahlstrom, M., & Weidolf, L. (2004). Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metabolism and Disposition, 32(8), 821–827.PubMedCrossRef

go back to reference Stockl, K. M., Le, L., Zakharyan, A., Harada, A. S., Solow, B. K., Addiego, J. E., et al. (2010). Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Archives of Internal Medicine, 170(8), 704–710.PubMedCrossRef Stockl, K. M., Le, L., Zakharyan, A., Harada, A. S., Solow, B. K., Addiego, J. E., et al. (2010). Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Archives of Internal Medicine, 170(8), 704–710.PubMedCrossRef

go back to reference Kreutz, R. P., Stanek, E. J., Aubert, R., Yao, J., Breall, J. A., Desta, Z., et al. (2010). Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy, 30(8), 787–796.PubMedCrossRef Kreutz, R. P., Stanek, E. J., Aubert, R., Yao, J., Breall, J. A., Desta, Z., et al. (2010). Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy, 30(8), 787–796.PubMedCrossRef

go back to reference Ray, W. A., Murray, K. T., Griffin, M. R., Chung, C. P., Smalley, W. E., Hall, K., et al. (2010). Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Annals of Internal Medicine, 152(6), 337–345.PubMed Ray, W. A., Murray, K. T., Griffin, M. R., Chung, C. P., Smalley, W. E., Hall, K., et al. (2010). Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Annals of Internal Medicine, 152(6), 337–345.PubMed

go back to reference O'Donoghue, M., Antman, E. M., Braunwald, E., Murphy, S. A., Steg, P. G., Finkelstein, A., et al. (2009). The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology, 54(8), 678–685.PubMedCrossRef O'Donoghue, M., Antman, E. M., Braunwald, E., Murphy, S. A., Steg, P. G., Finkelstein, A., et al. (2009). The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology, 54(8), 678–685.PubMedCrossRef

go back to reference Bhatt, D. L., Cryer, B. L., Contant, C. F., Cohen, M., Lanas, A., Schnitzer, T. J., et al. (2010). Clopidogrel with or without omeprazole in coronary artery disease. The New England Journal of Medicine, 363(20), 1909–1917.PubMedCrossRef Bhatt, D. L., Cryer, B. L., Contant, C. F., Cohen, M., Lanas, A., Schnitzer, T. J., et al. (2010). Clopidogrel with or without omeprazole in coronary artery disease. The New England Journal of Medicine, 363(20), 1909–1917.PubMedCrossRef

go back to reference Depta, J. P., & Bhatt, D. L. (2010). Omeprazole and clopidogrel: Should clinicians be worried? Cleveland Clinic Journal of Medicine, 77(2), 113–116.PubMedCrossRef Depta, J. P., & Bhatt, D. L. (2010). Omeprazole and clopidogrel: Should clinicians be worried? Cleveland Clinic Journal of Medicine, 77(2), 113–116.PubMedCrossRef

go back to reference Gurbel, P. A., & Tantry, U. S. (2011). Antiplatelet therapy: Clopidogrel–PPIs interaction, an ongoing controversy. Nature Reviews Cardiology, 8(1), 7–8.PubMedCrossRef Gurbel, P. A., & Tantry, U. S. (2011). Antiplatelet therapy: Clopidogrel–PPIs interaction, an ongoing controversy. Nature Reviews Cardiology, 8(1), 7–8.PubMedCrossRef

go back to reference Banerjee, S., Weideman, R. A., Weideman, M. W., Little, B. B., Kelly, K. C., Gunter, J. T., et al. (2011). Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. The American Journal of Cardiology, 107(6), 871–878.PubMedCrossRef Banerjee, S., Weideman, R. A., Weideman, M. W., Little, B. B., Kelly, K. C., Gunter, J. T., et al. (2011). Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. The American Journal of Cardiology, 107(6), 871–878.PubMedCrossRef

go back to reference Ferreiro, J. L., Ueno, M., Tomasello, S. D., Capodanno, D., Desai, B., Dharmashankar, K., et al. (2011). Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Circulation. Cardiovascular Interventions, 4(3), 273–279.PubMedCrossRef Ferreiro, J. L., Ueno, M., Tomasello, S. D., Capodanno, D., Desai, B., Dharmashankar, K., et al. (2011). Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Circulation. Cardiovascular Interventions, 4(3), 273–279.PubMedCrossRef